Skip to main content

Advertisement

SpringerLink
Log in

Disulfiram: a novel repurposed drug for cancer therapy

  • Review Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Cancer is a major health issue worldwide and the global burden of cancer is expected to reduce the costs of treatment as well as prolong the survival time. One of the promising approaches is drug repurposing, because it reduces costs and shortens the production cycle of research and development. Disulfiram (DSF), which was originally approved as an anti-alcoholism drug, has been proven safe and shows the potential to target tumours. Its anti-tumour effect has been reported in many preclinical studies and recently on seven types of cancer in humans: non-small cell lung cancer (NSCLC), liver cancer, breast cancer, prostate cancer, pancreatic cancer, glioblastoma (GBM) and melanoma and has a successful breakthrough in the treatment of NSCLC and GBM. The mechanisms, particularly the intracellular signalling pathways, still remain to be completely elucidated. As shown in our previous study, DSF inhibits NF-kB signalling, proteasome activity, and aldehyde dehydrogenase (ALDH) activity. It induces endoplasmic reticulum (ER) stress and autophagy and has been used as an adjuvant therapy with irradiation or chemotherapy drugs. On the other hand, DSF not only kills the normal cancer cells but also has the ability to target cancer stem cells, which provides a new approach to prevent tumour recurrence and metastasis. Furthermore, other researchers have reported the ability of DSF to bind to nuclear protein localization protein 4 (NPL4), induce its immobilization and dysfunction, ultimately leading to cell death. Here, we provide an overview of DSF repurposing as a treatment in preclinical studies and clinical trials, and review studies describing the mechanisms underlying its anti-neoplastic effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Johansson B (1992) A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand 369:15–26. https://doi.org/10.1111/j.1600-0447.1992.tb03310.x

    Article  CAS  Google Scholar 

  2. Wang Y, Li W, Patel SS, Cong J, Zhang N, Sabbatino F, Liu X, Qi Y, Huang P, Lee H, Taghian A, Li JJ, DeLeo AB, Ferrone S, Epperly MW, Ferrone CR, Ly A, Brachtel EF, Wang X (2014) Blocking the formation of radiation-induced breast cancer stem cells. Oncotarget 5(11):3743–3755

    Article  Google Scholar 

  3. Rae C, Tesson M, Babich JW, Boyd M, Sorensen A, Mairs RJ (2013) The role of copper in disulfiram-induced toxicity and radiosensitization of cancer cells. J Nucl Med 54(6):953–960. https://doi.org/10.2967/jnumed.112.113324

    Article  CAS  PubMed  Google Scholar 

  4. Skrott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, Ozdian T, Bartkova J, Turi Z, Moudry P, Kraus M, Michalova M, Vaclavkova J, Dzubak P, Vrobel I, Pouckova P, Sedlacek J, Miklovicova A, Kutt A, Li J, Mattova J, Driessen C, Dou QP, Olsen J, Hajduch M, Cvek B, Deshaies RJ, Bartek J (2017) Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 552(7684):194–199. https://doi.org/10.1038/nature25016

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Wu X, Xue X, Wang L, Wang W, Han J, Sun X, Zhang H, Liu Y, Che X, Yang J, Wu C (2018) Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer. Eur J Pharmacol 827:1–12. https://doi.org/10.1016/j.ejphar.2018.02.039

    Article  CAS  PubMed  Google Scholar 

  6. Barceloux DG (1999) Copper. J Toxicol Clin Toxicol 37(2):217–230. https://doi.org/10.1081/clt-100102421

    Article  CAS  PubMed  Google Scholar 

  7. Denoyer D, Masaldan S, La Fontaine S, Cater MA (2015) Targeting copper in cancer therapy: “copper that cancer.” Metallomics 7(11):1459–1476. https://doi.org/10.1039/c5mt00149h

    Article  CAS  PubMed  Google Scholar 

  8. Chen D, Cui QC, Yang H, Dou QP (2006) Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 66(21):10425–10433. https://doi.org/10.1158/0008-5472.CAN-06-2126

    Article  CAS  PubMed  Google Scholar 

  9. Dufour P, Lang JM, Giron C, Duclos B, Haehnel P, Jaeck D, Jung JM, Oberling F (1993) Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy 6(1):9–12. https://doi.org/10.1007/BF01877380

    Article  CAS  PubMed  Google Scholar 

  10. Lewison EF (1977) Spontaneous regression of breast cancer. Prog Clin Biol Res 12:47–53

    CAS  PubMed  Google Scholar 

  11. Liu P, Kumar IS, Brown S, Kannappan V, Tawari PE, Tang JZ, Jiang W, Armesilla AL, Darling JL, Wang W (2013) Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br J Cancer 109(7):1876–1885. https://doi.org/10.1038/bjc.2013.534

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Nechushtan H, Hamamreh Y, Nidal S, Gotfried M, Baron A, Shalev YI, Nisman B, Peretz T, Peylan-Ramu N (2015) A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer. Oncologist 20(4):366–367. https://doi.org/10.1634/theoncologist.2014-0424

    Article  PubMed  PubMed Central  Google Scholar 

  13. Schweizer MT, Lin J, Blackford A, Bardia A, King S, Armstrong AJ, Rudek MA, Yegnasubramanian S, Carducci MA (2013) Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. Prostate Cancer Prostatic Dis 16(4):357–361. https://doi.org/10.1038/pcan.2013.28

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Corsello SM, Nagari RT, Spangler RD, Rossen J, Kocak M, Bryan JG, Humeidi R, Peck D, Wu X, Tang AA, Wang VM, Bender SA, Lemire E, Narayan R, Montgomery P, Ben-David U, Garvie CW, Chen Y, Rees MG, Lyons NJ, McFarland JM, Wong BT, Wang L, Dumont N, O’Hearn PJ, Stefan E, Doench JG, Harrington CN, Greulich H, Meyerson M, Vazquez F, Subramanian A, Roth JA, Bittker JA, Boehm JS, Mader CC, Tsherniak A, Golub TR (2020) Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling. Nat Cancer 1(2):235–248. https://doi.org/10.1038/s43018-019-0018-6

    Article  PubMed  PubMed Central  Google Scholar 

  15. Triscott J, Rose Pambid M, Dunn SE (2015) Concise review: bullseye: targeting cancer stem cells to improve the treatment of gliomas by repurposing disulfiram. Stem Cells 33(4):1042–1046. https://doi.org/10.1002/stem.1956

    Article  CAS  PubMed  Google Scholar 

  16. Hald J, Jacobsen E (1948) A drug sensitizing the organism to ethyl alcohol. Lancet 2(6539):1001–1004. https://doi.org/10.1016/s0140-6736(48)91514-1

    Article  CAS  PubMed  Google Scholar 

  17. Cvek B (2012) Nonprofit drugs as the salvation of the world’s healthcare systems: the case of Antabuse (disulfiram). Drug Discov Today 17(9–10):409–412. https://doi.org/10.1016/j.drudis.2011.12.010

    Article  PubMed  Google Scholar 

  18. Cong J, Wang Y, Zhang X, Zhang N, Liu L, Soukup K, Michelakos T, Hong T, DeLeo A, Cai L, Sabbatino F, Ferrone S, Lee H, Levina V, Fuchs B, Tanabe K, Lillemoe K, Ferrone C, Wang X (2017) A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Cancer Lett 409:9–19. https://doi.org/10.1016/j.canlet.2017.08.028

    Article  CAS  PubMed  Google Scholar 

  19. He H, Markoutsa E, Li J, Xu P (2018) Repurposing disulfiram for cancer therapy via targeted nanotechnology through enhanced tumor mass penetration and disassembly. Acta Biomater 68:113–124. https://doi.org/10.1016/j.actbio.2017.12.023

    Article  CAS  PubMed  Google Scholar 

  20. Wang Z, Tan J, McConville C, Kannappan V, Tawari PE, Brown J, Ding J, Armesilla AL, Irache JM, Mei QB, Tan Y, Liu Y, Jiang W, Bian XW, Wang W (2017) Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. Nanomedicine 13(2):641–657. https://doi.org/10.1016/j.nano.2016.08.001

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Liu P, Wang Z, Brown S, Kannappan V, Tawari PE, Jiang W, Irache JM, Tang JZ, Armesilla AL, Darling JL, Tang X, Wang W (2014) Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo. Oncotarget 5(17):7471–7485

    Article  Google Scholar 

  22. Yip NC, Fombon IS, Liu P, Brown S, Kannappan V, Armesilla AL, Xu B, Cassidy J, Darling JL, Wang W (2011) Disulfiram modulated ROS-MAPK and NFkappaB pathways and targeted breast cancer cells with cancer stem cell-like properties. Br J Cancer 104(10):1564–1574. https://doi.org/10.1038/bjc.2011.126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Arora J, Sauer SJ, Tarpley M, Vermeulen P, Rypens C, Van Laere S, Williams KP, Devi GR, Dewhirst MW (2017) Inflammatory breast cancer tumor emboli express high levels of anti-apoptotic proteins: use of a quantitative high content and high-throughput 3D IBC spheroid assay to identify targeting strategies. Oncotarget 8(16):25848–25863

    Article  Google Scholar 

  24. Bista R, Lee DW, Pepper OB, Azorsa DO, Arceci RJ, Aleem E (2017) Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells. J Exp Clin Cancer Res 36(1):22. https://doi.org/10.1186/s13046-017-0493-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Jiao Y, Hannafon BN, Zhang RR, Fung KM, Ding WQ (2017) Docosahexaenoic acid and disulfiram act in concert to kill cancer cells: a mutual enhancement of their anticancer actions. Oncotarget 8(11):17908–17920

    Article  Google Scholar 

  26. Lun X, Wells JC, Grinshtein N, King JC, Hao X, Dang NH, Wang X, Aman A, Uehling D, Datti A, Wrana JL, Easaw JC, Luchman A, Weiss S, Cairncross JG, Kaplan DR, Robbins SM, Senger DL (2016) Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. Clin Cancer Res 22(15):3860–3875. https://doi.org/10.1158/1078-0432.CCR-15-1798

    Article  CAS  PubMed  Google Scholar 

  27. Papaioannou M, Mylonas I, Kast RE, Bruning A (2014) Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-mediated thioredoxin inhibition. Oncoscience 1(1):21–29

    Article  Google Scholar 

  28. Safi R, Nelson ER, Chitneni SK, Franz KJ, George DJ, Zalutsky MR, McDonnell DP (2014) Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res 74(20):5819–5831. https://doi.org/10.1158/0008-5472.CAN-13-3527

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Xu B, Wang S, Li R, Chen K, He L, Deng M, Kannappan V, Zha J, Dong H, Wang W (2017) Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-kappaB and Nrf2. Cell Death Dis 8(5):e2797. https://doi.org/10.1038/cddis.2017.176

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Triscott J, Lee C, Hu K, Fotovati A, Berns R, Pambid M, Luk M, Kast RE, Kong E, Toyota E, Yip S, Toyota B, Dunn SE (2012) Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget 3(10):1112–1123

    Article  Google Scholar 

  31. Park YM, Go YY, Shin SH, Cho JG, Woo JS, Song JJ (2018) Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death. PLoS ONE 13(9):e0203069. https://doi.org/10.1371/journal.pone.0203069

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Hassani S, Ghaffari P, Chahardouli B, Alimoghaddam K, Ghavamzadeh A, Alizadeh S, Ghaffari SH (2018) Disulfiram/copper causes ROS levels alteration, cell cycle inhibition, and apoptosis in acute myeloid leukaemia cell lines with modulation in the expression of related genes. Biomed Pharmacother 99:561–569. https://doi.org/10.1016/j.biopha.2018.01.109

    Article  CAS  PubMed  Google Scholar 

  33. Zha J, Chen F, Dong H, Shi P, Yao Y, Zhang Y, Li R, Wang S, Li P, Wang W, Xu B (2014) Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition. J Transl Med 12:163. https://doi.org/10.1186/1479-5876-12-163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Huang J, Chaudhary R, Cohen AL, Fink K, Goldlust S, Boockvar J, Chinnaiyan P, Wan L, Marcus S, Campian JL (2019) A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. J Neurooncol 142(3):537–544. https://doi.org/10.1007/s11060-019-03125-y

    Article  CAS  PubMed  Google Scholar 

  35. Huang J, Campian JL, Gujar AD, Tran DD, Lockhart AC, DeWees TA, Tsien CI, Kim AH (2016) A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. J Neurooncol 128(2):259–266. https://doi.org/10.1007/s11060-016-2104-2

    Article  CAS  PubMed  Google Scholar 

  36. Huang J, Campian JL, Gujar AD, Tsien C, Ansstas G, Tran DD, DeWees TA, Lockhart AC, Kim AH (2018) Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. J Neurooncol 138(1):105–111. https://doi.org/10.1007/s11060-018-2775-y

    Article  CAS  PubMed  Google Scholar 

  37. Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot JP, Guichet PO, Bian X, Armesilla AL, Darling JL, Wang W (2012) Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. Br J Cancer 107(9):1488–1497. https://doi.org/10.1038/bjc.2012.442

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Deng M, Jiang Z, Li Y, Zhou Y, Li J, Wang X, Yao Y, Wang W, Li P, Xu B (2016) Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram/copper complex in vitro and in vivo in patient-derived xenograft models. Oncotarget 7(50):82200–82212

    Article  Google Scholar 

  39. Zhang X, Hu P, Ding SY, Sun T, Liu L, Han S, DeLeo AB, Sadagopan A, Guo W, Wang X (2019) Induction of autophagy-dependent apoptosis in cancer cells through activation of ER stress: an uncovered anti-cancer mechanism by anti-alcoholism drug disulfiram. Am J Cancer Res 9(6):1266–1281

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Liu X, Wang L, Cui W, Yuan X, Lin L, Cao Q, Wang N, Li Y, Guo W, Zhang X, Wu C, Yang J (2016) Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells. Oncotarget 7(36):58516–58530

    Article  Google Scholar 

  41. Xu X, Xu J, Zhao C, Hou X, Li M, Wang L, Chen L, Chen Y, Zhu L, Yang H (2019) Antitumor effects of disulfiram/copper complex in the poorly-differentiated nasopharyngeal carcinoma cells via activating ClC-3 chloride channel. Biomed Pharmacother 120:109529. https://doi.org/10.1016/j.biopha.2019.109529

    Article  CAS  PubMed  Google Scholar 

  42. Allensworth JL, Evans MK, Bertucci F, Aldrich AJ, Festa RA, Finetti P, Ueno NT, Safi R, McDonnell DP, Thiele DJ, Van Laere S, Devi GR (2015) Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. Mol Oncol 9(6):1155–1168. https://doi.org/10.1016/j.molonc.2015.02.007

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Kast RE, Boockvar JA, Bruning A, Cappello F, Chang WW, Cvek B, Dou QP, Duenas-Gonzalez A, Efferth T, Focosi D, Ghaffari SH, Karpel-Massler G, Ketola K, Khoshnevisan A, Keizman D, Magne N, Marosi C, McDonald K, Munoz M, Paranjpe A, Pourgholami MH, Sardi I, Sella A, Srivenugopal KS, Tuccori M, Wang W, Wirtz CR, Halatsch ME (2013) A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. Oncotarget 4(4):502–530

    Article  Google Scholar 

  44. Conticello C, Martinetti D, Adamo L, Buccheri S, Giuffrida R, Parrinello N, Lombardo L, Anastasi G, Amato G, Cavalli M, Chiarenza A, De Maria R, Giustolisi R, Gulisano M, Di Raimondo F (2012) Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. Int J Cancer 131(9):2197–2203. https://doi.org/10.1002/ijc.27482

    Article  CAS  PubMed  Google Scholar 

  45. Lewis DJ, Deshmukh P, Tedstone AA, Tuna F, O’Brien P (2014) On the interaction of copper(II) with disulfiram. Chem Commun (Camb) 50(87):13334–13337. https://doi.org/10.1039/c4cc04767b

    Article  CAS  Google Scholar 

  46. Tesson M, Anselmi G, Bell C, Mairs R (2017) Cell cycle specific radiosensitisation by the disulfiram and copper complex. Oncotarget 8(39):65900–65916

    Article  Google Scholar 

  47. Skrott Z, Majera D, Gursky J, Buchtova T, Hajduch M, Mistrik M, Bartek J (2019) Disulfiram’s anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase. Oncogene 38(40):6711–6722. https://doi.org/10.1038/s41388-019-0915-2

    Article  CAS  PubMed  Google Scholar 

  48. Yoshino H, Yamada Y, Enokida H, Osako Y, Tsuruda M, Kuroshima K, Sakaguchi T, Sugita S, Tatarano S, Nakagawa M (2020) Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma. PLoS ONE 15(7):e0236119. https://doi.org/10.1371/journal.pone.0236119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Majera D, Skrott Z, Chroma K, Merchut-Maya JM, Mistrik M, Bartek J (2020) Targeting the NPL4 adaptor of p97/VCP segregase by disulfiram as an emerging cancer vulnerability evokes replication stress and DNA damage while silencing the ATR pathway. Cells. https://doi.org/10.3390/cells9020469

    Article  PubMed  PubMed Central  Google Scholar 

  50. Tacconi EM, Lai X, Folio C, Porru M, Zonderland G, Badie S, Michl J, Sechi I, Rogier M, Matia Garcia V, Batra AS, Rueda OM, Bouwman P, Jonkers J, Ryan A, Reina-San-Martin B, Hui J, Tang N, Bruna A, Biroccio A, Tarsounas M (2017) BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity. EMBO Mol Med 9(10):1398–1414

    Article  CAS  Google Scholar 

  51. Sun T, Yang W, Toprani SM, Guo W, He L, DeLeo AB, Ferrone S, Zhang G, Wang E, Lin Z, Hu P, Wang X (2020) Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram. Cell Commun Signal 18(1):36. https://doi.org/10.1186/s12964-019-0507-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Shah O’Brien P, Xi Y, Miller JR, Brownell AL, Zeng Q, Yoo GH, Garshott DM, O’Brien MB, Galinato AE, Cai P, Narula N, Callaghan MU, Kaufman RJ, Fribley AM (2019) Disulfiram (Antabuse) activates ROS-dependent ER stress and apoptosis in oral cavity squamous cell carcinoma. J Clin Med. https://doi.org/10.3390/jcm8050611

    Article  PubMed  PubMed Central  Google Scholar 

  53. Harrington BS, Ozaki MK, Caminear MW, Hernandez LF, Jordan E, Kalinowski NJ, Goldlust IS, Guha R, Ferrer M, Thomas C, Shetty J, Tran B, Wong N, House CD, Annunziata CM (2020) Drugs targeting tumor-initiating cells prolong survival in a post-surgery post-chemotherapy ovarian cancer relapse model. Cancers (Basel). https://doi.org/10.3390/cancers12061645

    Article  Google Scholar 

  54. Schmidtova S, Kalavska K, Gercakova K, Cierna Z, Miklikova S, Smolkova B, Buocikova V, Miskovska V, Durinikova E, Burikova M, Chovanec M, Matuskova M, Mego M, Kucerova L (2019) Disulfiram overcomes cisplatin resistance in human embryonal carcinoma cells. Cancers (Basel). https://doi.org/10.3390/cancers11091224

    Article  Google Scholar 

  55. Chiba T, Suzuki E, Yuki K, Zen Y, Oshima M, Miyagi S, Saraya A, Koide S, Motoyama T, Ogasawara S, Ooka Y, Tawada A, Nakatsura T, Hayashi T, Yamashita T, Kaneko S, Miyazaki M, Iwama A, Yokosuka O (2014) Disulfiram eradicates tumor-initiating hepatocellular carcinoma cells in ROS-p38 MAPK pathway-dependent and -independent manners. PLoS ONE 9(1):e84807. https://doi.org/10.1371/journal.pone.0084807

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Dinnen RD, Mao Y, Qiu W, Cassai N, Slavkovich VN, Nichols G, Su GH, Brandt-Rauf P, Fine RL (2013) Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC. Mol Cancer Ther 12(12):2792–2803. https://doi.org/10.1158/1535-7163.MCT-13-0234

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Hacker MP, Ershler WB, Newman RA, Gamelli RL (1982) Effect of disulfiram (tetraethylthiuram disulfide) amd diethyldithiocarbamate on the bladder toxicity and antitumor activity of cyclophosphamide in mice. Cancer Res 42(11):4490–4494

    CAS  PubMed  Google Scholar 

  58. Huang H, Liao Y, Liu N, Hua X, Cai J, Yang C, Long H, Zhao C, Chen X, Lan X, Zang D, Wu J, Li X, Shi X, Wang X, Liu J (2016) Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo. Oncotarget 7(3):2796–2808

    Article  Google Scholar 

  59. Swetha KL, Sharma S, Chowdhury R, Roy A (2020) Disulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagy. Pharmacol Rep. https://doi.org/10.1007/s43440-020-00122-1

    Article  PubMed  Google Scholar 

  60. Terashima Y, Toda E, Itakura M, Otsuji M, Yoshinaga S, Okumura K, Shand FHW, Komohara Y, Takeda M, Kokubo K, Chen MC, Yokoi S, Rokutan H, Kofuku Y, Ohnishi K, Ohira M, Iizasa T, Nakano H, Okabe T, Kojima H, Shimizu A, Kanegasaki S, Zhang MR, Shimada I, Nagase H, Terasawa H, Matsushima K (2020) Targeting FROUNT with disulfiram suppresses macrophage accumulation and its tumor-promoting properties. Nat Commun 11(1):609. https://doi.org/10.1038/s41467-020-14338-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Zhou B, Guo L, Zhang B, Liu S, Zhang K, Yan J, Zhang W, Yu M, Chen Z, Xu Y, Xiao Y, Zhou J, Fan J, Li H, Ye Q (2019) Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma. Am J Cancer Res 9(11):2442–2455

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Verma S, Stewart DJ, Maroun JA, Nair RC (1990) A randomized phase II study of cisplatin alone versus cisplatin plus disulfiram. Am J Clin Oncol 13(2):119–124. https://doi.org/10.1097/00000421-199004000-00007

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of China (81872426) and Natural Science Foundation of Jiangsu Province, China (BK20181372).

Author information

Author notes

  1. Chen Lu and Xinyan Li contributed equally to this work.

Authors and Affiliations

  1. Key Laboratory of Antibody Technology, National Health Commission, Nanjing Medical University, 101 Longmian Road, Nanjing, Jiangsu, China

    Chen Lu, Xinyan Li, Yongya Ren & Xiao Zhang

Authors
  1. Chen Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinyan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yongya Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiao Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xiao Zhang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, C., Li, X., Ren, Y. et al. Disulfiram: a novel repurposed drug for cancer therapy. Cancer Chemother Pharmacol 87, 159–172 (2021). https://doi.org/10.1007/s00280-020-04216-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-020-04216-8

Keywords

Search

Navigation